Pre-made Olendalizumab benchmark antibody ( Whole mAb, anti-C5/CO5 therapeutic antibody, Anti-CPAMD4/ECLZB Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Olendalizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Olendalizumab is a novel anti-inflammatory monoclonal antibody targeting complement protein C5a. Upon intravenous administration, anti-inflammatory antibody olendalizumab modulates the complement inflammatory pathway through binding to C5a.This inhibits C5a-mediated signal transduction, and results in the prevention and/or inhibition of both complement-mediated inflammation and cell destruction.
| Products Name (INN Index) | Pre-Made Olendalizumab biosimilar, Whole mAb, Anti-C5/CO5 Antibody: Anti-CPAMD4/ECLZB therapeutic antibody |
|---|---|
| INN Name | Olendalizumab |
| Target | C5 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2017 |
| Companies | Alexion Pharmaceuticals |
| Conditions Approved | NA |
| Conditions Active | Antiphospholipid syndrome,Graft-versus-host disease |
| Conditions Discontinued | Inflammation |
| Development Tech | NA |
| Previous Name | lendalizumab |
| Gm Offical Target Name | C5 |
| Package |
